Table 1

Baseline (week 0) characteristics of study participants

BMI
Greater than 30 (Obese)
25 – 29 (Overweight)

Treatment
Placebo (n = 30)
Formulation/no diet (n = 31)
Formulation/Diet (n = 31)
Formulation/no diet (n = 31)

Demographic Characteristics (no.)




Sex




     Male
14
15
14
15
     Female
16
16
17
16
Age (years)*
39.9 (9.6)
41.0 (9.4)
40.9 (9.8)
39.7 (9.9)
Race or ethnic group




     West African
30
31
31
31
Family History of Diabetes
2
1
0
2
History of Gestational Diabetes
2
2
3
2





Anthropomorphic Characteristics*1




Weight (kg)
95.6 (14.3)
95.8 (8.0)
95.3 (9.1)
76.3 (7.9)
Fat (%)
41.8 (5.2)
46.5 (5.8)
48.1 (3.0)
35.8 (5.2)
Body Mass Index (kg/m2)
38.4 (1.6)
37.7 (1.5)
37.5 (1.0)
27.3 (0.7)
Waist Circumference (cm)
103.4 (8.1)
98.6 (4.6)
97.8 (5.7)
86.9 (3.2)





Serological Characteristics*2




Total Cholesterol (mg/dl)
160.8 (18.0)
159.1 (30.7)
171.0 (24.4)
152.6 (26.9)
LDL Cholesterol (mg/dl)
103.5 (14.9)
99.8 (11.7)
116.6 (15.4)
101.6 (17.0)
HDL Cholesterol (mg/dl)
32.7 (7.5)
36.6 (8.0)
38.6 (7.1)
44.4 (9.8)
Triglycerides (mg/dl)
142.5 (31.8)
156.0 (25.3)
144.9 (30.0)
117.4 (25.3)
C-Reactive Protein (mg/dl)
8.0 (1.1)
8.0 (1.0)
8.1 (0.7)
7.8 (0.8)
Fasting Blood Glucose (mg/dl)
101.6 (11.9)
101.2 (15.9)
102.4 (9.8)
93.3 (12.4)

* These data are shown as means with standard deviations in parentheses

1 Primary outcome measures

2 Secondary outcome measures

Oben et al. Lipids in Health and Disease 2006 5:24   doi:10.1186/1476-511X-5-24